Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups

Scandinavian Journal of Urology and Nephrology

Volumn 36, Issue 2, 2002, Pages 106-112

  Sandblom, G ^a   Holmberg, L ^b   Damber, J E ^c   Hugosson, J ^c   Johansson, J E ^d   Lundgren, R ^e   Mattsson, E ^b   Nilsson, J ^b   Varenhorst, E ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^e HELSINGBORG HOSPITAL   (Sweden)

Author keywords

Prostate specific antigen; Prostatic neoplasms; Registries

Indexed keywords

GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES;

EID: 0036233120     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655902753679382     Document Type: Article

References (18)

1. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
2. Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer
3. Prediction of pathological stage and clinical outcome in prostate cancer: An improved preoperative model incorporating biopsy-determined intraductal carcinoma
4. Trends in prostate cancer survival in Sweden 1960 through 1988: Evidence of increasing diagnosis of nonlethal tumors
5. Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen era
6. Prostate cancer registration in four Swedish regions 1996. Differences in incidence, age structure and management
7. Recent results of management of palpable clinically localized prostate cancer
8. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
9. Staging errors in prostatic cancer
10. Reference material for PSA: The IFCC standardization study
11. Age-specific reference values for serum prostate-specific antigen in a community-based population of healthy Swedish men
12. Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor
13. The role of increasing detection in the rising incidence of prostate cancer
14. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota
15. Cancer surveillance series: Interpreting trends in prostate cancer - Part 3: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality
16. Patterns of treatment of patients with prostate cancer initially managed with surveillance: Results from the CaPSURE database